Merck to Acquire Cidara Therapeutics, Inc.

Fried Frank is advising Goldman Sachs & Co. LLC as financial advisor to Cidara in connection with the biotechnology company's agreement to be acquired by Merck, through a subsidiary, for $221.50 per share in cash, representing a total transaction value of approximately $9.2 billion. Read the companies' press release for more information.

This transaction is another example of Fried Frank's continued work advising top banks as financial advisors on high-value deals, which includes the firm previously advising Goldman Sachs as exclusive financial advisor to Hologic on its agreement to be acquired by funds managed by Blackstone and TPG and Fifth Third Bancorp on its merger agreement with Comerica Incorporated.

The Fried Frank team is led by corporate partners Roy Tannenbaum and Philip Richter and includes corporate associate Jenny Li.

This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm's data policy page for further information.